Found 17 clinical trials
Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer (MA-CRC-II-018)
The goal of this clinical trial is to learn if SHR-1701 combine with chemoradiotherapy works to treat severe CRC.Participants will take:Induction: SHR-1701 combined with CAPOX for one cycle. Radiotherapy: Short-course radiotherapy (SCRT) (25Gy/5F). Consolidation: SHR-1701 combined with CAPOX for five cycles, after which the subjects undergo TME surgery.
- 0 views
- 19 Mar, 2026
- 2 locations
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
JCOG1801 is a randomized phase III trial which was initiated in Japan in August 2019 to confirm the superiority of preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for local relapse-free survival over standard treatment, i.e. surgery plus adjuvant chemotherapy, for previously non-irradiated locally recurrent rectal cancer.
- 0 views
- 19 Feb, 2024
- 45 locations
S0820, Adenoma and Second Primary Prevention Trial (PACES)
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing the event rate of adenomas and second primary colorectal cancers at three years in patients previously treated for stage 0 to III colon or rectal cancer.
- 0 views
- 02 Dec, 2024
- 1 location
A Trial of Neoadjuvant mXELOXIRI Versus CRT in the EMVI Positive LARC
Extramural Vascular Invasion Positive(EMVI+) is a high risk of distant metastasis for locally advanced rectal cancer(LARC) after resection. The study is to evaluate the efficacy and safety of XELOXIRI as neoadjuvant chemotherapy alone for EMVI+ LARC in contrast to the efficacy of standard Chemoradiotherapy (CRT).
- 0 views
- 19 Feb, 2024
- 1 location
Microbiome and Rectal Cancer
The purpose of our study is to determine if an association exists between the microbiome of those with rectal adenocarcinoma who are complete pathologic responders and those who have a partial or no response to neoadjuvant therapy.
- 0 views
- 19 Feb, 2024
- 3 locations
Patient-Derived Organoids for Rectal Cancer
The purpose of this study is to determine the feasibility of establishing patient-derived organoids from pre-treatment rectal adenocarcinoma biopsies.
- 0 views
- 19 Feb, 2024
- 1 location
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
The objective is to learn if this treatment approach may safely be used as an alternative to the standard treatment for rectal cancer and to know the quality-of-life in these patients.
- 0 views
- 19 Feb, 2024
- 1 location
Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer
The addition of durvalumab to total neoadjuvant therapy (TNT) in locally advanced rectal cancer may improve the pathological complete response rate. The induction platinum-based chemotherapy may increase the neoantigen formation together with the chemoradiotherapy period.
- 0 views
- 19 Feb, 2024
- 10 locations
Neoadjuvant mFOLFOXIRI Plus Bevacizumab With Selective Radiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer
A small single-center phase II pilot trial treated patients with stage II or III rectal cancer with induction FOLFOX/bevacizumab chemotherapy followed by CRT only in those with stable or progressive disease and resection in all patients.
- 0 views
- 19 Feb, 2024
- 1 location
Urinary and Sexual Dysfunctions Evaluation After Rectal Resection
Advances in the treatment of rectal cancer over the past two decades have improved survival and significantly reduced surgery-related morbidity. As a result, post-treatment quality of life (QoL) issues have become increasingly important.
- 0 views
- 19 Feb, 2024
- 1 location
- 1
- 2